Filing Flows › AstraZeneca (AZN) › R&D spending
AstraZeneca (AZN) R&D spending by quarter
AstraZeneca's R&D spending was $4.1B in Q2 2026 (second quarter 2026), +11% from Q3 2025. Over the last 3 quarters it ranged from $3.5B (Q2 2025) to $4.1B (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.1B | +11% | +14% |
| Q3 2025 | $3.7B | +3% | — |
| Q2 2025 | $3.5B | — | — |
Q2 2026 at a glance
AstraZeneca, Q2 2026: revenue $15.4B (+6% year over year), operating margin 20.6%, net earnings $2.5B, operating cash flow $4.6B. The chart follows the revenue to costs, profit and cash.
Questions
What is AstraZeneca's R&D spending?
AstraZeneca's R&D spending was $4.1B in Q2 2026 (second quarter 2026), +11% from Q3 2025.
How has AstraZeneca's R&D spending changed?
Over the last 3 quarters it ranged from $3.5B (Q2 2025) to $4.1B (Q2 2026).